Biotest AG and AERES Biomedical Successfully Complete Engineering of the Antibody BT-062
26-Jan-2005
After BT-062 had shown impressive efficacy in an animal model of the disease, this is an important step towards the clinical development of the candidate. With tolerability and early efficacy displayed by BT-061 and BT-063 in patients with rheumatoid arthritis and systemic lupus erythematosus, respectively, BT-062 will be Biotest´s third monoclonal antibody entering clinical trials.
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.